Summary
Methenamine (hexamethylenetetramine, hexamine, urotropine) is a compound discovered in 1859, which is still currently being used as a urinary antiseptic. Methenamine is highly soluble in water and polar solvents, and its molecular constitution is similar to adamantane compounds with tetrahedral cage like structure. In acidic conditions, methenamine decomposes to formaldehyde and ammonia. Recently, methenamine has gained a renewal of interest due to antibiotic-resistant bacteria urinary tract infections; interestingly, bacteria cannot gain resistance to formaldehyde. In 1968,
David and Burkitt reported remarkable regression of four Burkitt Lymphoma patients
in eight subjects who were treated with septicemine (a solution containing 6.3 g of methenamine iodomethylate and 1 g of methenamine sodium benzoate in 100 cc distilled water). Unfortunately, these striking observations did not gain interest in the medical community; despite experimental models that showed that methenamine synergized with hyperthermia, radiation, and chemotherapy to block cancer growth.
As the hypoxic core of tumours have an acidic pH, it would be plausible to expect that methenamine would selectively target dormant, non-proliferative, and treatment-resistant cancer clones in large tumours. Moreover, previous data suggests that methenamine can be safely used intravenously and for treatment of infections of the central nervous system. It may therefore be an effective adjuvant in treatment of systemic cancers and glioblastoma.
K E Y W O R D S
cancer, hypoxic sensitization, methenamine we will show: (a) that it can be relatively safely employed at high dosages; (b) its efficacy in systemic and central nervous system infections; (c) its therapeutic activity in a small pilot study in Burkitt lymphoma; (d) its anticancer efficacy in cell culture and animal models of cancer; and (e) its likely activation and release of formaldehyde in hypoxic and acidic cores of tumours to induce cytotoxicity alone and in synergy with chemo-radiotherapy (Table 1 ). Due to the Warburg effect, cancer cells preferentially use the glycolytic pathway to produce energy even when sufficient oxygen levels are available; glycolysis yields the production of high levels of lactate causing an acidity within tumours. Additionally, due to fast growth and proliferation, cancer tissue is often inadequate to supply oxygen and other nutrients, which enhances anaerobic metabolism and contribute to the acidic microenvironment in cancerous tissues (a range from pH 6.5 to 6.9 compared to a range from pH 7.2 to 7.4 in normal tissue).
Methenamine is a tertiary amine; when hydrolyzed in cellular micromilieu (in low pH values), it yields ammonia and formaldehyde and releases six formaldehyde molecules ( Figure 1) . 2 Formaldehyde triggers cell death by inducing the formation of an irreversible -CH2
cross-link between the primary amine groups of proteins and the nearby nitrogen atoms in protein or DNA ( Figure 2 ). 3 Tumours are acidic due to anaerobic metabolism of cancer cells under normoxia (known as the Warburg effect); 2 this acidity further increases in hypoxic core regions of tumours. Due to the acidic microenvironment of tumours, methenamine would be preferentially hydrolyzed to release formaldehyde within tumours; an effect that would be enhanced in chemo-radiotherapy refractory hypoxic regions leading to increased chemo-radiosensitivity.
| ME THENAMINE . B IOAVAIL AB ILIT Y, PHARMACOLOGY, S IDE EFFEC TS AND B I OSAFE T Y
Oral methenamine is readily absorbed, and more than 80% of methenamine is excreted with urine in healthy subjects, indicating a very good oral bioavailability. 4 Methenamine mandelate is sold as an enteric coated tablet, while methenamine hippurate is marketed in nonenteric coating form. The half-life of methenamine elimination from serum is 3-4 hours in patients with normal renal function.
4
Methenamine concentrations in blood serum could be obtained up to 14 mmol/L in dogs and 300 μmol/L in humans. 5 In a Swedish study, it was revealed that 1 g of methenamine hippurate twice a severe. These side effects of methenamine and the indications for nanoparticle drug delivery will be discussed below.
| ME THENAMINE ' S INTR AVENOUS USAG E AND APPLI C ATI ON FOR SYS TEMI C AND NEUROLOG IC AL INFEC TIONS
Following its discovery in 1859 by Aleksandr Butlerov, first medical usage of methenamine was reported in 1894, which demonstrated its prominent efficacy as a urinary antiseptic, including sterilization of urine in patients with typhoid fever. 6 Thereafter, clinical studies were conducted in cholecystitis, appendicitis, encephalitis, and meningitis. 7 In 1919, intravenous usage of methenamine was reported for the treatment of rheumatoid diseases at very large doses (90 grain, about 5.8 g). 8 In 1920, successful intravenous usage of methenamine was reported for treatment of post-operative urine retention and antiseptic prophylaxis in various surgical operations, involving urinary and biliary tract, and meninges. 9 In rural India, safe and successful usage of intravenous methenamine was reported in cystitis, suppurative skin infections, and in wide-spread scabies. 10 In 1927, it was reported that intravenous methenamine had therapeutic value in second degree burn cases complicated by intense suppuration. 11 In 1928, Bhattacharyya reported that he employed intravenous methenamine treatment for the treatment of influenza and associated broncho-pneumonitis with exceptional success. 7 He prepared solutions of 15 grains F I G U R E 1 Molecular structure of methenamine and its decomposition products formaldehyde and ammonia (972 mg) of methenamine dissolved in 4 mL of sterile water, and administered intravenously. 7 He also used intravenous methenamine to successfully treat patients with acute and chronic nephritis without haematuria, as is seen with oral application. 7 It was also proposed that Herpesviri are especially sensitive to the therapeutic efficacy of methenamine. 12 Crowe revealed that orally administered methenamine was detectable in cerebro-spinal fluid collected through lumbar puncture 1 hour following application. 13 He also demonstrated that treatment with methenamine following subdural inoculation of dogs and rabbits with streptococci, inhibited the onset of meningitis, and hence, he advised its routine use prior to neurosurgical operations. 13 Conversely, Guthrie reported that methenamine was not detectable in the cerebrospinal fluid 1 hour after oral application. However, these data were only based on two cases, and the pharmacokinetics of methenamine may vary among patients due to such physiological difference as gastric acidity. 13 In 1920,
Crawshaw reported a 12-year-old girl with encephalitis lethargica who showed significant improvement following methenamine treatment. 8 In 1934, Chopra reported successful treatment of a severe meningococcal central nervous system infection with intravenous methenamine in twelve injections over a 1-month period. 14 Harvey
Cushing, the father of modern neurosurgery, also employed methenamine in the treatment of brain abscess. 15 Following the discov- 
| ME THENAMINE APPLI C ATI ON FOR C AN CER TRE ATMENT IN E XPERIMENTAL MODEL S
In 1973, it was shown that methenamine enhanced survival of mice inoculated with Ehrlich ascites carcinoma; survival was further enhanced when concurrent buffered solutions with low pH values and/or glucose were applied. 5 In this study, glucose boosted the acidic lactate production through the enhanced glycolytic metabolism of cancer cells. In 1989, Reitz and Jaeger showed that 0.2 mg/ mL (cell culture volume) of methenamine blocked L5178M lymphoma cell growth by 94%. 12 The authors further showed that low 
| ME THENAMINE SYNERG IS M WITH ADRIAMYCIN
Adriamycin (doxorubicin) is one of the most widely employed chemotherapeutic agents and is used in treatment of mammary, pulmonary, thyroid, and ovarian carcinomas, as well as Hodgkin's and non-Hodgkin's lymphomas and leukaemias. 2 Adriamycin and other anthracyclines are anticancer agents that block topoisomerase II activity and induce iron-enhanced formation of adriamycin-DNA adducts. 2 However, subsequent studies revealed that the Fe(III)/DTT/ Tris buffer caused the formation of formaldehyde which mediated the production of the drug-DNA adducts. necessary for the synthesis of purines, thymidine, and some amino acids. 3 However, given that formaldehyde metabolism may damage the DNA, it is quickly metabolized by reductive, oxidative, and reduced glutathione-associated pathways. 3 Cells exposed to formaldehyde undergo DNA-protein crosslinks as a main form of DNA damage. 3 Moreover, formaldehyde donates a methylene group that links the 3′ amino of adriamycin to the 2′ amino of deoxyguanosine residues of DNA; this formaldehyde-conjugated complex is the active form of the drug. 
DNA adducts.
2 Formation of these adducts were dependent on pH, with a 4-fold increase at a pH of 6.5 vs 7.4, consistent with the lability of methenamine in the acidic microenvironment. 2 Adriamycin and methenamine combination resulted in a 3-fold lower IC 50 value compared with that of adriamycin alone. 2 The authors also revealed that methenamine induced adriamycin-DNA adducts developed specifically at GpC sites, and methenamine activated other anthracyclines including daunorubicin, idarubicin, and, to a lesser extent, epirubicin. 2 The authors underlined that such a combination would be suitable in treatment of tumours with a pH of <6.8, including GBM, breast carcinomas, and those with a pH of <6.4 including squamous cell carcinomas, sarcomas, meningiomas, and astrocytomas. 
TA B L E 1 Biochemical rationale by which methenamine exerts its antitumor and therapy sensitizing effects

High glycolysis induces an acidic micromillieu in cancer tissues
Methenamine decomposes to formaldehyde and urea at acidic microenvironment The Methenamine's decomposition product formaldehyde kills cells via protein and DNA crosslinking
Immune mechanisms are considered to mediate antitumor effects of methenamine in cases with Burkitt lymphoma Saturation of formaldehyde metabolism causes DNA damage; hence, it is quickly metabolized by reductive, oxidative and reduced glutathione-associated pathways
Cancer cells already contain high amounts of oxidant injury; thus, processing of formaldehyde-induced injury may shift the oxidant/anti-oxidant balance to intolerable levels and cause tumouricidal cytotoxicity
Formaldehyde donates a methylene group that links the 3′ amino of adriamycin to the 2′ amino of deoxyguanosine residues of DNA and enhances the anticancer activity of adriamycine Adriamycine-chemosensitization with methenamine was more potent in quiescent cancer cells (which stay dormant at G0 phase of the cell cycle), which may survive following chemo-radiotherapy and carry the potential to repopulate the tumour mass
Hence, methenamine may act as a potent tool to eradicate treatment-resistant cancer cell clones
Methenamine is also capable to sensitize cancer cells to the tumouricidal action of cisplatin and radiotherapy
Methenamine exerts dual benefits in combination with hyperthermia. It enhances tumouricidal activity of hyperthermia while preventing body toxicity of hyperthermia via preventing thermal proteolysis When loaded within nanoliposomes, methenamine induces an arrest of the cell cycle in S-phase with concomitant phosphorylation of checkpoint kinases chk1 and chk2
induces DNA damage response and subsequent apoptosis of human breast cancer cells in vitro and in mouse xenografts 
| ME THENAMINE SYNERG IS M WITH CIS PL ATIN AND R AD IATI ON
| ME THENAMINE SYNERG IS M WITH HYPERTHERMIA
Hyperthermia is a heat-treatment modality that targets malignant cells or their microenvironment; it is generally assumed that significant cancer cell death could be induced if malignant tissues were heated to over 42°C for 1 hour or longer. 21 It is also presumed that hyperthermia would induce radiation and chemotherapy sensitization, partly through inhibition of the DNA damage repair machinery. 21 For cancer treatment protocols, standard whole body More importantly, methenamine mandelate and NaHCO 3 -loaded nanoparticles significantly blocked the tumoural growth of MCF-7
human breast cancer xenografts in vivo. 24 
| R ATIONALE FOR EMPLOYING ME THENAMINE TO TRE AT AND CHEMO -R ADIO -S ENS ITIZE G LIOBL A S TOMA
As suggested, methenamine has been successfully applied to treat central nervous system infections in the past, suggesting that it crosses through the blood-brain barrier and releases cytocidal levels formaldehyde in hypoxic tissues. In tumours, hypoxia aggravates chemotherapy and radiotherapy resistance, and glioblastomas are among the most hypoxic of solid tumours. 25 Hypoxic cell clones do not actively divide due to lack of sufficient cellular energy and non-dividing cells are more resistant to chemo-radiotherapy as their DNA is more compacted and shielded with histone and non-histone proteins. Moreover, hypoxia activates purinergic signalling allowing multi-drug resistance in glioblastoma. 26 Furthermore, hypoxia can directly induce the transformation of glioblastoma cells into a glioblastoma stem cell phenotype 27 which enhances their invasive features. 28 Overall, it seems very plausible to employ methenamine treatment to target and kill hypoxic and resistant cell clones in glioblastoma tissues. 
| CON CLUS IONS
